Saliva-Based DNA Collection Product Chosen for Study to Identify Host Correlates of Protection Against Tuberculosis
OTTAWA, July 29 /PRNewswire/ - DNA Genotek, a leading provider of products for biological sample collection, stabilization and preparation, today announced that the world's leading TB vaccine research site, the South African Tuberculosis Vaccine Initiative (SATVI), has chosen Oragene-DNA for a study aimed at identifying host correlates of protection against TB, following BCG vaccination.
This study is looking at the genetic differences between infants who are either protected or not protected against TB, following BCG vaccination. The researchers are also interested in determining if there is a genetic predisposition to susceptibility of TB by recruiting parents of both protected and unprotected infants. Over the course of the 4 year study, approximately 6,000 DNA samples will be collected with the Oragene-DNA Self-Collection Kits.
Oragene-DNA is an all-in-one system for the collection, stabilization, transportation and purification of DNA from saliva that enables easy, reliable and cost effective collection of samples from large numbers of individuals while providing high quality DNA. The product provides DNA sample stability at ambient temperatures, making it ideal for remote collection in sub-Saharan Africa.
Muki Shey, student researcher coordinating the study at SATVI, which is based at the University of Cape Town, is upbeat about using the product. "We believe the Oragene-DNA system is the most practical for collecting DNA in our environment. Our field site is located in a poor rural area covering an area of about 12,000 square km. TB is highly endemic in the region, which has one of the highest rates in sub-Sah
|SOURCE DNA Genotek Inc.|
Copyright©2010 PR Newswire.
All rights reserved